心脏移植后三发性难治性免疫球蛋白轻链淀粉样变患者对单药 Bcl-2 抑制剂 Venetoclax 的快速完全缓解。

Rapid Complete Response to Single-Agent Bcl-2 Inhibitor Venetoclax in a Heart-Transplanted Patient with Triple Refractory Immunoglobulin Light-Chain Amyloidosis.

机构信息

Department of Medicine, Karolinska Institutet, Stockholm, Sweden,

Department of Clinical Chemistry, Karolinska University Hospital, Stockholm, Sweden,

出版信息

Acta Haematol. 2020;143(5):500-503. doi: 10.1159/000504355. Epub 2020 Jan 2.

DOI:10.1159/000504355

PMID:31896106

Abstract

Immunoglobulin light-chain amyloidosis (AL) is a disease with limited treatment options due to the frailty of patients caused by organ damage. Since the clonal plasma cells often contain the cytogenetic aberration t(11;14), the Bcl-2 inhibitor venetoclax is suggested to have a role in the treatment of AL. Here, we report of a heart-transplanted patient, refractory to multiple therapies, reaching a rapid complete response with single-agent venetoclax.

摘要

免疫球蛋白轻链淀粉样变（AL）是一种疾病，由于器官损伤导致患者虚弱，治疗选择有限。由于克隆性浆细胞通常含有细胞遗传学异常 t（11；14），因此 Bcl-2 抑制剂 venetoclax 被认为在 AL 的治疗中具有作用。在这里，我们报告了一例心脏移植患者，对多种治疗方法均耐药，用单药 venetoclax 达到快速完全缓解。